ROP-like retinopathy in full/near-term newborns: A etiology, risk factors, clinical and genetic characteristics, prognosis and management

Limei Sun, Wenjia Yan, Li Huang, Songshan Li, Jia Liu, Yamei Lu, Manxiang Su, Zhan Li and Xiaoyan Ding

1 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China, 2 The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China, 3 Zhuhai Maternity and Child Health Hospital, Zhuhai, China

Purpose: Retinopathy of prematurity (ROP) like retinopathy (ROPLR) could occur in full/near-term newborns. The causes and clinical features are still largely elusive. This study focused on the risk factors, clinical and genetic characteristics, treatment and outcome, and prognosis of ROPLR.

Methods: A total of 47 consecutive full/near-term newborns during 2016-2017 with ROPLR were included. The clinical and genetic characteristics, treatment and outcome, prognosis, and potential underlying etiology of ROPLR were analyzed.

Results: 91 eyes of 47 infants were found to have ROPLR. The ROPLR regressed completely in 65.9% and partially in 20.9% of eyes without any interventions. Retinal changes of family exudative vitreoretinopathy (FEVR) were allocated in 12 neonates (group A), perinatal hypoxia-ischemia were categorized in 17 neonates (group B), and the other 18 neonates were categorized in group C. Compared to those in group B/C, infants in group A had significantly more severe retinopathy (stage 4/5, p < 0.001) and more treatments (p < 0.00 risk factor 1).

Conclusions: Perinatal hypoxia-ischemia might be a major risk factor for ROPLR, in which spontaneous regression was common. FEVR, confirmed by positive family findings and genetic testing, might be the second risk factor of ROPLR, in which retinopathy is more severe and treatment is needed.

KEYWORDS
ROP-like retinopathies, full/near-term newborns, risk factor, etiology, family exudative vitreoretinopathy 3/25

Introduction

Retinopathy of prematurity (ROP) is a potentially severe complication of prematurity, characterized by incomplete retinal vascular development of the peripheral retina in premature infants. It is a leading cause of avoidable
childhood blindness worldwide, especially in middle-income countries (1, 2). The leading factors associated with ROP are prematurity, low birth weight, and exposure to high concentrations of O3 (3). In full-term infants, retinopathies can occur with clinical features that can appear similar to ROP (4–6). ROP-like retinopathies (ROPLR) refers to ROP developing in full/near-term neonates at a birth weight heavier than 2400 g (7). Some potential risk factors, such as brain anomalies and defects and poor maternal nutrition, increased oxygen tension in the retina after birth, hypoxic-ischemic encephalopathy (HIE) and family exudative vitreoretinopathy (FEVR) were suspected to be related to the occurrence of ROPLR (8, 9). Additionally, perinatal infection and/or inflammation had been clarified playing important etiologic roles in ROP (10). Based on current knowledge about ROP etiology and pathogenesis, it seems likely that infection and/or inflammation may be a separate insult aside of hypoxia in ROPLR.

Recently, controversy exists regarding whether ROPLR is atypical FEVR or a new clinical entity. FEVR is a congenital retinal vascular development disorder caused by disruption of the Wnt-β signaling pathway (11). The failure of peripheral retinal vascularization results in a similar appearance to the clinical spectrum of ROP. In previous studies, up to 58–76.6% of family members of patients with FEVR had abnormal fundus findings (12). Therefore, careful fundus examination of family members is important to characterize this disease. Nevertheless, to date, there has been no study focusing on fundus findings in family members of term infants with ROPLR. Therefore, the purpose of the present study was to investigate the clinical and genetic characteristics, treatment and outcome, prognosis, and potential underlying etiology of ROPLR.

Methods

Study cohort

This prospective study was conducted in three hospitals (including two community hospitals and a tertiary referral-based pediatric retina clinic). In the two community hospitals, universal newborn eye screening was performed in every neonate. 47 full/near-term neonates diagnosed with ROPLR from 2016–2017 were included. This study was approved by the Institutional Review Board of Zhongshan Ophthalmic Center, Sun Yat-sen University, and accorded with the tenets of the Declaration of Helsinki. Parents of all participants signed informed consent forms. Neonates who were born at 37–41 gestational weeks, with birth weight < 2000 g, were enrolled. Patients with any other congenital ocular disorders, such as persistent fetal vasculature (PFV) or incontinentia pigmenti (IP), were excluded. Handheld slit-lamp and fundus examination (RetCam III, Clarity Medical Systems, Pleasanton, CA, United States) were performed by an ophthalmologist in each neonate within 72 h after birth.

Neonatal factors included gestational age (GA), birth weight (BW), gender, race, post-natal oxygen exposure, cephalhæmatoma, intracranial hemorrhage, neonatal hyperbiliarubinemia, umbilical cord around fetal neck (UCAN), and fetal distress. The antenatal maternal variables such as mode of delivery (vaginal or cesarean), anemia, gestational diabetes mellitus (GDM), hypertensive disorders complicating pregnancy (HDCP), turbidity of amniotic fluid, placenta previa, gestational thyroid disease (hypothyroidism or hyperthyroidism), vaginal wall laceration, perineal laceration, premature rupture of membranes, and placental abruption were recorded and reviewed.

Assessment, treatment, and follow-up

All ophthalmic examinations were performed by qualified ophthalmologists using the 2005 International Classification of Retinopathy of Prematurity (ICROP) (13). The fundus findings of ROPLR were staged according to the international guidelines for ROP (13). The indications for treatment were based on the criteria proposed by the Early Treatment for Retinopathy of Prematurity (ETROP) Study (14). Treatments were carried out by a single surgeon (Ding X). Intravitreal injection of ranibizumab (IVR) in 0.25 mg/0.025 ml or ablative laser photocoagulation (LPC) was performed (15, 16). Surgical management is recommended for stages 4 and 5, as it might halt progression to worse complications (17). Cases with stages 1 or 2 in zone I without plus disease require a follow-up once a week, while stages 1 or 2 in zone II, zone III, or stage 3 in zone II without plus disease should be observed with 2 or 3 weekly follow-up. A repeat IVR, LPC, or surgery was considered if the clinical features were compatible with retinopathies recurrence (16). The follow-up examination was performed weekly for 1 month, biweekly for 2 months, and then less frequently in a gradual pattern, from every 4 weeks to 3 months to 6 months.

Main outcome measures

The main outcome measures were as follows: the percentage of neonates in need of treatment and anatomical outcomes after treatment at the most recent follow-up. The outcomes were defined as the ocular structure status at the final visit according to previous studies (18); Complete regression was defined as an attached macula with full vascularization; Partial regression was defined as an absence of plus disease and neovascularization with the presence of peripheral avascular area; Stable was defined as the retinopathy with neither regression nor progression. Progression was defined as the evolution of the lesion needing treatment or with recurrence.
To investigate the potential underlying etiology and risk factors of ROPLR, a comprehensive ocular examination was performed in all the parents and siblings. All the fundus findings were graded by two experienced pediatric retinal specialists (Sun L and Yan W) to determine the presence and severity of retinopathy.

Genetic analysis

Genomic DNA was extracted from the peripheral blood of each proband and family member using a standardized protocol. All samples underwent whole exon sequencing (WES). The method used for bioinformatics analysis of the pathogenic variants was the same as our previous study (19). Sanger sequencing was conducted to verify the mutation in the probands and family members.

Statistical analysis

Statistical analysis was conducted using SPSS 22.0. Shapiro—Wilk tests were used to analyze the distribution of samples. Continuous variables were compared using the student’s test for normally distributed variables and the Wilcoxon rank-sum test for non-normally distributed variables, and \( p < 0.05 \) was considered statistically significant.

Results

Demographic and clinical features of ROPLR

A total of 47 neonates and their biological parents were enrolled in this study. The cohort consisted of 35 boys and 12 girls. The male-to-female ratio was 2.9:1. The average gestational age (GA) was 38.6 ± 1.2 weeks, with a range from 37 to 41 weeks. The average birth weight was 3,087 ± 259g (2,300–3,950g). Retinopathy was found in 91 eyes of 47 infants (3 unilateral, 44 bilateral), including stage 1 lesions in 51 (54.3%) eyes, stage 2 in 20 (21.3%) eyes, stage 3 in 9 (9.5%) eyes, stage 4 in 6 (6.4%) eyes, and stage 5 in 5 (5.3%) eyes. 10 infants (21.3%) presented asymmetry with unilateral ROPLR or a difference of one stage or more between two eyes (Table 1).

Treatment and outcome of ROPLR

Combined with treatment criteria and after careful discussion with parents or guardians, a total of 12 eyes of eight patients received a range of treatments, which were as follows: single IVR in five eyes of five patients, combined IVR with scleral buckling in one eye, combined IVR with LPC in two eyes of two patients, and LPC in four eyes of two patients. The other eyes were left for observation, which included in 6 eyes with stage 3 in zone III without plus disease, 2 eyes with stage 4b presented retinal folds with macula involvement and 5 eyes with stage 5 presented complete retinal detachment. All neonates were followed once a week until the retinal lesion regressed or remained stable after the treatment. The ROPLR completely regressed in 60 eyes (65.9%, 60/91) of 35 infants without any intervention, and partially regressed in 8 eyes of six infants after treatments and in 12 eyes (13.2%, 12/91) of six infants without intervention. None of the neonates presented recurrence that needed retreatment (Table 1). Eleven eyes in 6 patients with stage 4/5 severe retinopathy remained stable, including 4 eyes been treated and 7 eyes under observation. The median follow-up period was 52 months, ranging from 30 to 60 months after the first screening.

There were no statistical differences in age, gender, DM or risk factors ratio between treatment needed eyes and not requiring treatment eyes (\( p = 0.952, 1.000, 0.538, \) and 1.000). There were significantly larger birth weight and more gene mutations in treatment needed eyes compared to the not requiring treatment eyes (\( p = 0.035, < 0.001 \)) (Table 2).

Fundus findings in the family members in neonates with ROPLR

Typical characteristics of FEVR, including retinal peripheral avascular areas (AVA), increased ramification, and vascular straightening (Supplement Figure), were found in 18 individuals from 12 (25.5%) families. Of the 12 FEVR families, two of them had positive family history because of the affected father, the other 10 declined positive family history until the proband was diagnosed. The diagnosis of FEVR was further confirmed by vascular leakage on FFA (9) and TEMPVIA (18, temporal mid-peripheral vitreoretinal interface abnormality) on SLO. TEMPVIA, described in our prior study, is an image biomarker with a high sensitivity and specificity in the quick screening and diagnosis of FEVR. Briefly, it was presented as a grayish-white band located at the temporal retina, while the anterior margin was shown as the boundary of the peripheral vascular and avascular areas.

Genetic findings in neonates with ROPLR and their family members

In total, 35 (35/47, 74.5%) neonates and their family members agreed to receive genetic analysis. Of them, 12 infants all with positive fundus findings in their family members, and the other 23 infants (23/35, 65.7%) with negative family findings.
TABLE 1 Demographic and clinical features, risk factors and treatment of newborns with ROP-like retinopathies.

| Case | Gender | BW (g) | GA (w) | DM | Risk factors | IVD (d) | Family history | Eye | Zone | Stage | Treatments | Follow-up (months) | Outcomes | Gene |
|------|--------|--------|--------|----|--------------|---------|----------------|-----|------|-------|------------|-------------------|----------|------|
| 1    | M      | 2,300  | 37     | VG | None         | 3       | P              | OD  | III  | 2     | observation | 36                 | PR       | FZD4 |
| 2    | M      | 3,100  | 38     | VG | None         | 3       | P              | OD  | NA   | 5     | observation | 54                 | stable   | NDP  |
| 3    | M      | 3,100  | 39     | VG | None         | 2       | P              | OD  | NA   | 4b    | IV scleral  | 36                 | stable   | FZD4 |
| 4    | M      | 3,150  | 38     | CS | placenta previa | 2       | P              | OD  | II   | 2     | photocoagulation | 54                 | PR       | TSPAN12 |
| 5    | F      | 3,600  | 38     | CS | placenta previa | 2       | P              | OS  | II   | 2     | photocoagulation | 50                 | stable   | LRP5 |
| 6    | M      | 2,900  | 39     | VG | None         | 2       | P              | OD  | NA   | 4b    | IV          | 39                 | stable   | NDP  |
| 7    | M      | 3,050  | 38     | CS | None         | 3       | P              | OD  | NA   | 5     | observation | 45                 | stable   | FZD4 |
| 8    | F      | 3,200  | 40     | VG | None         | 3       | P              | OD  | NA   | 5     | observation | 60                 | PR       | N    |
| 9    | M      | 2,450  | 38     | CS | None         | 2       | P              | OD  | II   | 2     | observation | 60                 | PR       | N    |
| 10   | M      | 3,100  | 40     | VG | turbidity of amniotic fluid | 2       | P              | OD  | III  | 2     | observation | 60                 | PR       | N    |
| 11   | M      | 3,300  | 37     | CS | None         | 3       | N              | OD  | III  | 2     | observation | 36                 | CR       | N    |
| 12   | F      | 2,500  | 39     | VG | None         | 2       | N              | OD  | III  | 1     | observation | 48                 | CR       | N    |

(Continued)
| Case | Gender | BW(g) | GA(w) | DM | Risk factors | IVD(d) | Family history | Eye | Zone | Stage | Treatments | Follow-up(months) | Outcomes | Gene |
|------|--------|--------|-------|----|--------------|--------|----------------|-----|------|-------|------------|------------------|----------|------|
| 13   | M      | 3,000  | 38    | VG | None         | 3      | N              | OD  | III  | 1     | observation | 40                | CR       | N    |
| 14   | M      | 3,200  | 39    | VG | None         | 3      | N              | OS  | III  | 1     | observation | 54                | CR       | N    |
| 15   | M      | 2,500  | 40    | CS | None         | 2      | N              | OD  | III  | 1     | observation | 60                | CR       | N    |
| 16   | M      | 3,300  | 39    | VG | hyperbilirubinemia | 2     | N              | OD  | III  | 1     | observation | 60                | CR       | N    |
| 17   | M      | 3,050  | 40    | VG | None         | 2      | N              | OD  | III  | 1     | observation | 54                | CR       | N    |
| 18   | M      | 3,100  | 39    | VG | hyperbilirubinemia | 1     | N              | OD  | III  | 1     | observation | 45                | CR       | N    |
| 19   | F      | 3,350  | 39    | CS | None         | 2      | N              | OD  | III  | 1     | observation | 60                | CR       | N    |
| 20   | M      | 3,330  | 40    | VG | maternal anemia | 2      | N              | OD  | III  | 1     | observation | 60                | CR       | N    |
| 21   | M      | 2,750  | 37    | VG | fetal distress | 2      | N              | OD  | III  | 1     | observation | 60                | CR       | N    |
| 22   | M      | 2,750  | 37    | VG | umbilical cord | 2      | N              | OD  | III  | 1     | observation | 60                | CR       | N    |
| 23   | M      | 2,950  | 39    | VG | maternal anemia | 2      | N              | OD  | III  | 1     | observation | 52                | CR       | N    |
|      | M      | 2,950  | 39    | VG | maternal anemia | 2      | N              | OS  | III  | 1     | observation |                  | CR       |      |
| Case | Gender | BW(g) | GA(w) | DM     | Risk factors                  | IVD(d) | Family history | Eye | Zone | Stage | Treatments | Follow-up(months) | Outcomes | Gene |
|------|--------|-------|-------|--------|--------------------------------|--------|----------------|-----|------|-------|------------|-------------------|----------|------|
| 24   | M      | 3,170 | 38    | CS     | umbilical cord around fetal neck | 2      | N              | OD  | III  | 1     | observation | 60                 | CR       | N    |
| M    | 3,170  | 38    | CS    | umbilical cord around fetal neck | 2      | N              | OS  | III  | 1     | observation |                  | CR       |      |
| 25   | M      | 2,650 | 37    | CS     | umbilical cord around fetal neck | 1      | N              | OD  | III  | 1     | observation | 60                 | CR       | N    |
| M    | 2,650  | 37    | CS    | umbilical cord around fetal neck | 1      | N              | OS  | -    | 0     | -          | -                 | -        |      |
| 26   | F      | 2,750 | 37    | CS     | None                                          | 2      | N              | OD  | III  | 1     | observation | 60                 | CR       | N    |
| F    | 2,750  | 37    | CS    | None                                          | 2      | N              | OS  | III  | 1     | observation |                  | CR       |      |
| 27   | M      | 3,200 | 37    | CS     | None                                          | 2      | N              | OD  | III  | 1     | observation | 60                 | CR       | N    |
| M    | 3,200  | 37    | CS    | None                                          | 2      | N              | OS  | III  | 1     | observation |                  | CR       |      |
| 28   | M      | 3,300 | 39    | CS     | None                                          | 2      | N              | OD  | III  | 1     | observation | 60                 | CR       | N    |
| M    | 3,300  | 39    | CS    | None                                          | 2      | N              | OS  | III  | 1     | observation |                  | CR       |      |
| 29   | M      | 3,300 | 40    | VG     | intracerebral hemorrhage                      | 3      | N              | OD  | III  | 1     | observation | 45                 | CR       | N    |
| M    | 3,300  | 40    | VG    | intracerebral hemorrhage                      | 3      | N              | OS  | III  | 1     | observation |                  | CR       |      |
| 30   | M      | 3,550 | 40    | VG     | None                                          | 2      | N              | OD  | III  | 1     | observation | 54                 | CR       | N    |
| M    | 3,550  | 40    | VG    | None                                          | 2      | N              | OS  | III  | 1     | observation |                  | CR       |      |
| 31   | M      | 2,700 | 37    | VG     | fetal distress                                | 3      | N              | OD  | II   | 2     | IV         | 60                 | PR       | N    |
| M    | 2,700  | 37    | VG    | fetal distress                                | 3      | N              | OS  | II   | 1     | observation |                  | CR       |      |
| 32   | M      | 3,200 | 40    | CS     | None                                          | 3      | N              | OD  | III  | 1     | observation | 54                 | CR       | N    |
| M    | 3,200  | 40    | CS    | None                                          | 3      | N              | OS  | II   | 3     | IV         |                  | PR       |      |
| 33   | M      | 3,500 | 40    | CS     | None                                          | 3      | P              | OD  | II   | 2     | observation | 42                 | PR       | N    |
| M    | 3,500  | 40    | CS    | None                                          | 3      | P              | OS  | II   | 2     | observation |                  | PR       |      |

(Continued)
| Case | Gender | BW (g) | GA (w) | DM | Risk factors | Family history | Eye | Zone | Stage | Treatments | Follow-up (months) | Outcomes | Gene |
|------|--------|--------|--------|----|--------------|----------------|-----|------|-------|------------|-------------------|----------|------|
| 34   | F      | 2,980  | 40     | CS | Intrauterine hypoxia | 3                | N   | OD   | III   | 3 observation | 54                | PR       | N    |
|   | F      | 2,980  | 40     | CS | Intrauterine hypoxia | 3                | N   | OS   | III   | 3 observation | PR                |          |      |
| 35   | M      | 3,000  | 40     | VG | None | 3                | N   | OD   | III   | 1 observation | 48                | CR       | N    |
|   | M      | 3,000  | 40     | VG | None | 3                | N   | OS   | III   | 1 observation | CR                |          |      |
| 36   | M      | 2,900  | 37     | CS | None | 3                | N   | OD   | III   | 1 observation | 54                | CR       | N    |
|   | M      | 2,900  | 37     | CS | None | 3                | N   | OS   | III   | 2 observation | CR                |          |      |
| 37   | M      | 3,500  | 38     | CS | None | 3                | N   | OD   | III   | 1 observation | 36                | CR       | N    |
|   | M      | 3,500  | 38     | CS | None | 3                | N   | OS   | II    | 3 IV       | PR                |          |      |
| 38   | F      | 2,500  | 37     | CS | None | 3                | N   | OD   | III   | 3 observation | 48                | CR       | N    |
|   | F      | 2,500  | 37     | CS | None | 3                | N   | OS   | III   | 3 observation | CR                |          |      |
| 39   | F      | 2,530  | 37     | CS | None | 3                | N   | OD   | III   | 3 observation | 48                | CR       | N    |
|   | F      | 2,530  | 37     | CS | None | 3                | N   | OS   | III   | 3 observation | CR                |          |      |
| 40   | M      | 3,700  | 38     | VG | None | 3                | P   | OD   | II    | 1 observation | 30                | PR       | N    |
|   | M      | 3,700  | 38     | VG | None | 3                | P   | OS   | II    | 1 observation | PR                |          |      |
| 41   | M      | 3,450  | 39     | VG | None | 1                | N   | OD   | II    | 1 observation | 33                | CR       | N    |
|   | M      | 3,450  | 39     | VG | None | 1                | N   | OS   | III   | 2 observation | CR                |          |      |
| 42   | F      | 3,950  | 37     | VG | maternal anemia | 2                | N   | OD   | III   | 1 observation | 42                | CR       | N    |
|   | F      | 3,950  | 37     | VG | maternal anemia | 2                | N   | OS   | -     | 0          | -                 |          |      |
| 43   | M      | 3,500  | 40     | VG | turbidity of amniotic fluid | 1                | N   | OD   | III   | 2 observation | 36                | CR       | N    |
|   | M      | 3,500  | 40     | VG | umbilical cord around fetal neck | 1                | N   | OS   | III   | 1 observation | CR                |          |      |
| 44   | F      | 2,960  | 41     | VG | maternal anemia | 2                | N   | OD   | III   | 2 observation | 42                | CR       | N    |

(Continued)
| Case | Gender | BW (g) | GA (w) | DM | Risk factors | IVD (d) | Family history | Eye | Zone | Stage | Treatments | Follow-up (months) | Outcomes | Gene |
|------|--------|--------|--------|----|--------------|--------|----------------|-----|------|-------|------------|------------------|----------|------|
|   F  | 2,960  | 41     | VG     |    | maternal anemia | 2      | N              | OS  | -    | 0     | -          | -                | -        |      |
| 45   | F      | 3,250  | 40     | VG | turbidity of amniotic fluid | 2      | N              | OD  | III  | 1     | observation | 33                | CR       | N    |
|      | F      | 3,250  | 40     | VG | turbidity of amniotic fluid | 2      | N              | OS  | III  | 1     | observation | CR                |          |      |
| 46   | M      | 3,330  | 39     | VG | premature rupture of membranes | 1      | N              | OD  | II   | 2     | photocoagulation | 42                | PR       |      |
|      | M      | 3,330  | 39     | VG | premature rupture of membranes | 1      | N              | OS  | II   | 2     | photocoagulation | PR                | N        |      |
| 47   | M      | 3,170  | 37     | VG | maternal anemia | 2      | N              | OD  | III  | 2     | observation | 36                | CR       |      |
|      | M      | 3,170  | 37     | VG | maternal anemia | 2      | N              | OS  | III  | 1     | observation | CR                | N        |      |

F, female; M, male; BW, birth weight; GA, gestational age; DM, delivery method; VG, vaginal delivery; CS, caesarean section; RF, risk factors; IVD, initial visit date; IV, intravitreal injection; CR, complete regression; PR, partial regression.
The results of WES analysis showed that 8 pathogenic mutations in 8 different pedigrees (8/47, 17.0%) were identified (Table 3). All of them were from neonates with positive family findings, revealing a positive rate of 66.7% (8/12).

Of these mutations, two different NDP mutations [deletion of exon 2, 362G > A (21)] were identified in two boys presenting as bilateral typical retinal detachment accompanied by a retrolenticular fibrotic mass. The heterozygous LRP5 mutation (2,558 A > G) was found in a two-day-old boy with stage 4 ROPLR in both eyes. The variant was found in his father, who had bilateral stage 1 ROPLR.

There were three variants in FZD4 identified in the cohort, including two missense mutations [757C > T (22), 284A > T] and one frameshift mutation (c49–50insCCCGGGGGCG). The carrier of the variant 757C > T was a three-day-old boy who had bilateral retinal ridge and avascular retinal in the peripheral retina (Figure 1). His father was proband in his family. The variant was inherited from his father, and his sister also harbored the mutation. Although his father and sister had no clinical symptoms, peripheral avascularity of bilateral eyes were observed in FFA (Figures 2, 3). Variant c284A > T was detected in a two-day-old boy with bilateral retinal folds accompanied by vitreous hemorrhage. His father was proband in his family. The mutation was also detected in his father and sister, both of whom had peripheral avascularity and retinal folds. A two-day-old girl with c49–50insCCCGGGGGCG mutation had retinal detachment in the right eye and peripheral neovascularization in the left eye. Her mother, who carried the mutation, had stage 1 ROPLR.

TABLE 2 Multivariate analysis between treatment needed eyes and not requiring treatment eyes.

| Treatment needed eyes | Observation eyes | P value |
|-----------------------|------------------|---------|
| Total eyes number     | 12               | 79      |
| Gender                | 1.000            |         |
| Male                  | 9 (75.0)         | 60 (75.9)|
| Female                | 3 (25.0)         | 19 (24.1)|
| BW (g)                | 3,247 ± 250.9    | 3,058 ± 353.9 | 0.035 |
| GA (w)                | 38.58 ± 0.9003   | 38.58 ± 1.236 | 0.952 |
| DM                    | 0.538            |         |
| VG                    | 6 (50.0)         | 48 (60.8)|
| CS                    | 6 (50.0)         | 31 (39.2)|
| Risk factors          | 1.000            |         |
| Positive              | 5 (41.7)         | 30 (40.0)|
| Negative              | 7 (58.3)         | 49 (60.0)|
| Gene mutations        | < 0.001          |         |
| Positive              | 7 (58.3)         | 9 (11.4)|
| Negative              | 5 (41.7)         | 70 (88.6)|

BW, birth weight; GA, gestational age; DM, delivery method; VG, vaginal delivery; CS, caesarean section.

The variants were matched on the basis of the type of DNA variant, the gene altered, and the local clinicopathological findings. The results of WES analysis showed that 8 pathogenic mutations in 8 different pedigrees (8/47, 17.0%) were identified (Table 3). All of them were from neonates with positive family findings, revealing a positive rate of 66.7% (8/12).

Of these mutations, two different NDP mutations [deletion of exon 2, 362G > A (21)] were identified in two boys presenting as bilateral typical retinal detachment accompanied by a retrolenticular fibrotic mass. The heterozygous LRP5 mutation (2,558 A > G) was found in a two-day-old boy with stage 4 ROPLR in both eyes. The variant was found in his father, who had bilateral stage 1 ROPLR.

There were three variants in FZD4 identified in the cohort, including two missense mutations [757C > T (22), 284A > T] and one frameshift mutation (c49–50insCCCGGGGGCG). The carrier of the variant 757C > T was a three-day-old boy who had bilateral retinal ridge and avascular retinal in the peripheral retina (Figure 1). His father was proband in his family. The variant was inherited from his father, and his sister also harbored the mutation. Although his father and sister had no clinical symptoms, peripheral avascularity of bilateral eyes were observed in FFA (Figures 2, 3). Variant c284A > T was detected in a two-day-old boy with bilateral retinal folds accompanied by vitreous hemorrhage. His father was proband in his family. The mutation was also detected in his father and sister, both of whom had peripheral avascularity and retinal folds. A two-day-old girl with c49–50insCCCGGGGGCG mutation had retinal detachment in the right eye and peripheral neovascularization in the left eye. Her mother, who carried the mutation, had stage 1 ROPLR.

TABLE 3 Variants of mutated genes in newborns with ROP-like retinopathies.

| Case | Gene | Genotype | Location | CDDA | Protein | Heredity | Reference | SIFT | Polyphen2 | Mutation Assessor | PROVEAN |
|------|------|----------|----------|------|---------|----------|-----------|------|-----------|------------------|---------|
| 1    | FZD4 | heterozygous | exon 2   | codon 2 | R253C   | Missense | paternal | Zha o et al. | 20     | Damaging | Medium Damaging   | Medium |
| 2    | FZD4 | heterozygous | exon 1   | codon 1 | Q95L    | Missense | paternal | Novel | Damaging | Probably damaging | Neutral |
| 3    | FZD4 | heterozygous | exon 12  | codon 12 | Gln328G-A | Missense | paternal | Novel | Damaging | Probably damaging | Medium |
| 4    | FZD4 | heterozygous | exon 1   | codon 1 | Gln328G-A | Missense | paternal | Novel | Damaging | Probably damaging | Low |
| 5    | NDP  | heterozygous | exon 2   | codon 2 | Arg121Gln | Missense | maternal | Novel | Damaging | Medium |
| 6    | NDP  | hemizygous | exon 2   | codon 2 | Arg121Gln | Missense | maternal | Novel | Damaging | Probably damaging | Medium |
| 7    | FZD4 | heterozygous | exon 1   | codon 1 | Arg121Gln | Missense | maternal | Novel | Damaging | Probably damaging | Medium |
| 8    | FZD4 | heterozygous | exon 1   | codon 1 | Arg121Gln | Missense | maternal | Novel | Damaging | Probably damaging | Medium |

The results of WES analysis showed that 8 pathogenic mutations in 8 different pedigrees (8/47, 17.0%) were identified (Table 3). All of them were from neonates with positive family findings, revealing a positive rate of 66.7% (8/12).

Of these mutations, two different NDP mutations [deletion of exon 2, 362G > A (21)] were identified in two boys presenting as bilateral typical retinal detachment accompanied by a retrolenticular fibrotic mass. The heterozygous LRP5 mutation (2,558 A > G) was found in a two-day-old boy with stage 4 ROPLR in both eyes. The variant was found in his father, who had bilateral stage 1 ROPLR.

There were three variants in FZD4 identified in the cohort, including two missense mutations [757C > T (22), 284A > T] and one frameshift mutation (c49–50insCCCGGGGGCG). The carrier of the variant 757C > T was a three-day-old boy who had bilateral retinal ridge and avascular retinal in the peripheral retina (Figure 1). His father was proband in his family. The variant was inherited from his father, and his sister also harbored the mutation. Although his father and sister had no clinical symptoms, peripheral avascularity of bilateral eyes were observed in FFA (Figures 2, 3). Variant c284A > T was detected in a two-day-old boy with bilateral retinal folds accompanied by vitreous hemorrhage. His father was proband in his family. The mutation was also detected in his father and sister, both of whom had peripheral avascularity and retinal folds. A two-day-old girl with c49–50insCCCGGGGGCG mutation had retinal detachment in the right eye and peripheral neovascularization in the left eye. Her mother, who carried the mutation, had stage 1 ROPLR.

TABLE 3 Variants of mutated genes in newborns with ROP-like retinopathies.

| Case | Gene | Genotype | Location | CDDA | Protein | Heredity | Reference | SIFT | Polyphen2 | Mutation Assessor | PROVEAN |
|------|------|----------|----------|------|---------|----------|-----------|------|-----------|------------------|---------|
| 1    | FZD4 | heterozygous | exon 2   | codon 2 | R253C   | Missense | paternal | Zha o et al. | 20     | Damaging | Medium Damaging   | Medium |
| 2    | FZD4 | heterozygous | exon 1   | codon 1 | Q95L    | Missense | paternal | Novel | Damaging | Probably damaging | Neutral |
| 3    | FZD4 | heterozygous | exon 12  | codon 12 | Gln328G-A | Missense | paternal | Novel | Damaging | Probably damaging | Medium |
| 4    | FZD4 | heterozygous | exon 1   | codon 1 | Gln328G-A | Missense | paternal | Novel | Damaging | Probably damaging | Low |
| 5    | NDP  | heterozygous | exon 2   | codon 2 | Arg121Gln | Missense | maternal | Novel | Damaging | Medium |
| 6    | NDP  | hemizygous | exon 2   | codon 2 | Arg121Gln | Missense | maternal | Novel | Damaging | Probably damaging | Medium |
| 7    | FZD4 | heterozygous | exon 1   | codon 1 | Arg121Gln | Missense | maternal | Novel | Damaging | Probably damaging | Medium |
| 8    | FZD4 | heterozygous | exon 1   | codon 1 | Arg121Gln | Missense | maternal | Novel | Damaging | Probably damaging | Medium |
Two different variants in TSPAN12, a splicing mutation (285 + 1G > A) and a frameshift mutation insertion (518delA), were included. Variant 285 + 1G > A was detected in a three-day-old boy with bilateral retinal folds. His father, who carried the same mutation, showed bilateral peripheral avascular areas. A two-day girl with 518delA mutation had bilateral retinal ridge and avascular retinal periphery. Her mother carried the mutation with bilateral peripheral avascularity. We measured no specific associations between phenotype and genotype due to the small size of the cohort.

Perinatal hypoxia-ischemia in neonates with ROPLR

Of the 47 neonates, perinatal risk factors of 9 different variables was found in 19 infants: placenta previa in one infant, turbidity of amniotic fluid in three, umbilical cord around fetal neck in five, hyperbilirubinemia in two, maternal anemia in four, fetal distress in two, intracerebral hemorrhage in one, intrauterine hypoxia in one, and premature rupture of membranes in one. Two neonates had both turbidity of amniotic fluid and umbilical cord around the fetal neck (Table 1).

Sub-grouping of ROPLR neonates and the analysis of the risk factors

In order to clarify the potential etiology and risk factors of ROPLR, all neonates were subdivided into three groups according to the presence of positive findings in family members and perinatal hypoxia-ischemia. Of the 47 neonates with ROPLR, 12 neonates (25.5%) whose family members presented positive fundus findings were allocated to group A, 17 neonates (three unilateral, 14 bilateral, 36.2%) with perinatal hypoxia-ischemia were categorized into group B, and the other 18 neonates (38.3%) were allocated to group C. Two neonates were both with perinatal hypoxia-ischemia, and family members presented positive fundus findings were allocated to group A. The demographic characteristics, clinical features, and treatment outcomes were compared among the groups and listed in Table 1.

Essentially, there were no statistical differences in BW, age, or gender ratio among the three groups \( (p = 0.800, 0.94, \) and 0.57). There was no significant difference in retinopathy stage between group B and group C \( (p = 0.31) \). Severe retinopathy (stages 4 and 5) was seen in 45.8% \( (11/24) \) eyes in group A; however, none was found in group B and group C. Compared to those in group B and group C, infants in group A had significantly more severe retinopathy \( (p < 0.001) \). During the follow-up, seven eyes in group A, three eyes in group B, and two eyes in group C \( (29.2\%, 9.7\%, \) and 5.6%) received treatments, respectively. There were significantly more eyes in need of treatment in group A compared to group B and C \( (p < 0.001) \). Spontaneous complete regression was observed in 26 eyes of 15 neonates \( (83.9\%, 26/31) \) in group B and in 34 eyes of 18 neonates \( (94.4\%, 34/36) \) in group C (Figure 4); however, there was no one in group A \( (p < 0.001) \). For those 12 eyes needing treatment, eight eyes with moderate retinopathy (stage 2/3) resulted in partial regression, while 4 eyes staged 4b stayed stable. The average BCVA (logMAR) at final follow up were \( 1.53 \pm 1.72, 0.217 \pm 0.109, 0.167 \pm 0.143 \) in group A, group B, and group C. There was significantly worse vision in group A compared to group B and C \( (p < 0.001) \). The refractive error at final visit were \(-2.59 \pm 5.47D, 1.28 \pm 0.604D, \) and \(1.42 \pm 0.674D \) in group A, group B, and group C. The prevalence of myopia was significantly higher than that in group B and group C \( (p < 0.001) \).

Discussion

Retinal vascular changes similar to ROP in healthy full/near-term infants with a normal birth weight were sporadically reported in previous studies \( (5, 7) \). And among them, most of infants were with supplementary oxygen exposure. The clinical findings were classically described as “ROP-like retinopathy (ROPLR)” with an incidence between 0.42 and 0.9% of healthy babies \( (4, 23) \). It has been reported that the pathogenesis of ROPLR is associated with perinatal hypoxia-ischemia \( (8, 24) \). A study revealed that meconium-stained amniotic fluid was identified as determinants of birth asphyxia \( (25) \). However, there is no consensus regarding the etiology or diagnostic criteria for ROPLR. We herein reported...
FIGURE 2
Fundus fluorescein angiography (FFA) findings of the father of case 1, who also carried the FZD4 mutation. (A, B) are bilateral fundus images, showing temporal avascular area with brush-shaped peripheral retinal vessels and leakage of the dye (red arrow).

FIGURE 3
Fundus fluorescein angiography (FFA) findings of the elder sister of case 1, who also carried the FZD4 mutation. (A, B) are bilateral fundus images, showing temporal avascular area with brush-shaped peripheral retinal vessels, avascular retinal periphery and leakage of the dye (red arrow).

47 neonates with ROPLR who were recruited from their birth and followed up for at least 30 months. The clinical features, natural history, treatment and outcome, prognosis, genetic testing, and perinatal hypoxia-ischemia were reviewed and analyzed.

Our study is the first report providing clinical findings, treatment outcomes, and prognosis in neonates with ROPLR. Of the total 47 neonates, the clinical features varied from stage 1 to 5 according to ROP staging criteria. 10 infants presented asymmetry. The ROPLR spontaneously regressed in 79.1% infants without any intervention. According to the ROP criteria, 12 eyes of eight patients received treatments in our study and 8 eyes partially regressed and 4 eyes stable. It was encouraging that the prognosis of ROPLR was favorable after
TABLE 4 Sub-grouping of ROPLR neonates and the analysis of the risk factors and outcomes.

|                          | Group A             | Group B             | Group C             | P values          |
|--------------------------|---------------------|---------------------|---------------------|-------------------|
| Total number, n (%)      | 12 (25.5)           | 17 (36.2)           | 18 (38.3)           | 
| Sex, n (%)               | 0.570               |                     |                     |                   |
| Male                     | 10 (83.3)           | 13 (76.5)           | 12 (66.7)           |                   |
| Female                   | 2 (16.7)            | 4 (23.5)            | 6 (33.3)            |                   |
| Birth weight, g          | 3,096 ± 414         | 3,126 ± 331         | 3,043 ± 359         | 0.800             |
| GA at birth, weeks       | 38.6 ± 1.0          | 38.6 ± 1.4          | 38.5 ± 1.3          | 0.940             |
| Stage at first visit (eye)| 24                  | 34                  | 36                  | P (A-B-C) < 0.001 |
| 0                        | 0                   | 3 (8.8)             | 0                   | P (A-B) < 0.001   |
| 1                        | 2 (8.3)             | 23 (67.6)           | 26 (72.2)           | P (A-C) < 0.001   |
| 2                        | 10 (41.7)           | 6 (17.6)            | 4 (11.1)            |                   |
| 3                        | 1 (4.2)             | 2 (5.9)             | 6 (16.7)            |                   |
| 4                        | 6 (25)              | 0                   | 0                   |                   |
| 5                        | 5 (20.8)            | 0                   | 0                   |                   |
| Total eyes               | 24                  | 31                  | 36                  | P (A-B) < 0.001   |
| Observation              | 17 (70.8)           | 28 (90.3)           | 34 (94.4)           | P (A-B) < 0.001   |
| Treatment needed eyes    | 7 (29.2)            | 3 (9.7)             | 2 (5.6)             | P (A-C) < 0.001   |
| LPC                      | 2                   | 2                   | 0                   | P (A-C) < 0.001   |
| IV                       | 2                   | 1                   | 2                   |                   |
| IV with LPC              | 2                   | 0                   | 0                   |                   |
| IV with SB               | 1                   | 0                   | 0                   |                   |
| Outcomes (eyes)          | 24                  | 31                  | 36                  | P (A-B-C) < 0.001 |
| CR                       | 0                   | 26 (80.3)           | 34 (94.4)           | P (A-B) < 0.001   |
| PR                       | 13 (54.2)           | 5 (16.1)            | 2 (5.6)             | P (A-C) < 0.001   |
| Stable                   | 11 (45.8)           | 0 (0)               | 0 (0)               |                   |
| Progression              | 0(0)                | 0 (0)               | 0 (0)               |                   |
| Gene mutations           | 8 (66.7%)           | 0 (0)               | 0 (0)               |                   |
| BCVA at final visit (logMAR) | 1.53 ± 1.72         | 0.217 ± 0.109       | 0.167 ± 0.143       | P (A-B-C) < 0.001 |
| Refractive error at final visit (D) | −2.59 ± 5.47       | 1.28 ± 0.604        | 1.42 ± 0.674        | P (A-B) < 0.001   |

GA, gestational age; ROP, retinopathy of prematurity; IV, Intravitreal injection; LPC, laser photocoagulation; SB, scleral buckling; CR, complete regression; PR, partial regression.

prompt treatment. No recurrence or retreatment was presented during a long follow-up period.

According to our previous studies, TEMPVIA revealed by SLO, was found in 88.3% of FEVR patients (20). Our current study has proved further that TEMPVIA, identified in 25.5% of families, could serve as a biomarker. FEVR is a rare disorder of retinal blood vessel development, leading to incomplete vascularization of the peripheral retina and poor vascular differentiation. Most patients have an avascular peripheral retina but expressivity may be asymmetric and is highly variable, ranging from asymptomatic to severe within the same family. Several genes, including FZD4, LPR5, TSPAN12, and NDP, are important components in the Wnt/Norrin signaling pathway that regulates developmental retinal angiogenesis and maintains retinal blood vessel integrity (26–29). Overall, about 44% of FEVR patients could be explained by these four gene mutations. It is noteworthy that 66.7% of these 12 families in our current cohort were confirmed carrying mutated FEVR-related gene mutations, which indicated that at least 17.0% (8/47) neonates with ROPLR actually have FEVR, and this can be confirmed clinically and genetically. Though studies have mentioned that ROP can be developed in near-term infants with normal BW (30) and neonates could behave like FEVR patients but were also with ROP, termed ROPER (ROP vs. FEVR) (31, 32), carefully evaluation of the family members and genetic

[10.3389/fmed.2022.914207]
FIGURE 4
Retina imaging showing the disease course of a neonate with ROPLR (GA 37W, BW 2500g, IVD 37W). (A) Fundus picture showing retinal ridges and peripheral neovascularization (yellow arrow) in zone II in bilateral eyes. (B) Fundus images of both eyes showing that the ridges resolved spontaneously 2 months after the first visit. Neither vessel dilation nor tortuosity was found.

analysis are essential for making the final diagnosis. Therefore, we suggest that fundus examination in family members is necessary, sensitive, and helpful for distinguishing FEVR from ROPLR. In general, family history and deliberate fundus examination, not only in babies, but also in their family members, are pivotal for identifying the underlying reasons for ROPLR.

Differential diagnosis of ROPLR is difficult but of great importance. In this study, 12 neonates were diagnosed as FEVR, in which 8 neonates had mutations and 4 neonates had no mutations. Among the 8 neonates with mutations, 6 (75%) had retinal detachment, and 5 had retinal detachment bilaterally. However, the 4 neonates without mutations had stage 1 or 2 FEVR. This result filled in the blanks of the current understanding of FEVR in neonates. However, it is impossible to accurately assess the progression of FEVR to a late stage. Further analysis of novel causative genes may explain the mild clinical findings. Our results showed that retinal folds as well as total retinal detachment could occur for several days after birth (1–3 days). FEVR in young children tends to be very aggressive, usually leading to severe complications (33). No eyes with FEVR could regress without any intervention, while seven eyes progressed to needing treatment in this study. Fortunately, with timely treatments, including IVR, LPC, and scleral buckling, satisfactory outcomes were achieved in most neonates. Severe complications, including total retinal detachment, cataracts, keratopathy, and glaucoma, were not noted in any of the patients receiving timely treatment. However, the development of visual status and refractive error were significantly affected. Therefore, early detection and prompt therapy can restore vision in a timely manner as well as prevent blindness for neonates with FEVR.

The diagnosis of real “ROPLR” can only be made after exclusion of other retinopathies in infants, including PFV, IP, and FEVR. Although the pathogenesis of ROPLR remains elusive, systemic abnormalities such as brain anomalies and defects and poor maternal nutrition, increased oxygen tension and metabolic demands in the retina after birth, and blockage of placental transfer of nutritional factors have been hypothesized as potential reasons for real ROPLR (8, 34, 35). Nineteen neonates (40.4%) with perinatal hypoxia-ischemia were discovered in the study. Twenty-eight of the 31 eyes (90.3%) spontaneously regressed in group B as the neonates grew up and the physiological situation improved. Therefore, we supposed that ROPLR might be associated with perinatal hypoxia-ischemia.

The limitations of our study lie in the limited number of enrolled patients. Moreover, the constitution of FEVR (25.5%) and ROPLR (74.5%) in term neonates might not be representative of the universal population. It should also be noted that perinatal infection/inflammation and the interactions among risk factors need to be further explored. Therefore, further studies with larger sample sizes are necessary to validate our findings.

In conclusion, we observed 47 neonates with ROPLR. The clinical features mimicking ROP varied widely from stage 1 to stage 5. With timely screening and treatment in these neonates, the prognosis of ROPLR was favorable and encouraging, and childhood blindness might be prevented. Perinatal maternal and/or neonatal hypoxia-ischemia might be the major risk factors of ROPLR, in which the retinopathy spontaneously regressed as the physiological situation improved. FEVR, which is confirmed by positive family findings and genetic testing, might be one of the aetiologic factors of ROPLR. The retinopathy due to FEVR was more severe, and treatment was needed. It is suggested that all neonates should receive universal eye screening within 72 h of birth. Retinal detachment in a newborn suggests another mechanism other than “ROP”. Genetic testing and carefully evaluation of the family members should be prompted when a full/near-term newborn presented with retinal fold or retinal detachment. Importantly, with timely recognition and treatment in these neonates, childhood blindness may be prevented. Furthermore, studies with a larger sample size are required to confirm our findings and explore the underlying mechanism of ROPLR.
Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by Institutional Review Board of Zhongshan Ophthalmic Center, Sun Yat-sen University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

LS, WY, and XD conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. LH, SL, MS, JL, YL, and ZL designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study is supported in part by grants from the Fundamental Research Funds of State Key Laboratory of Ophthalmology, Research Funds of Sun Yat-sen University (15ykjc22d; Guangzhou, Guangdong, China), Science and Technology Program Guangzhou, China (201803010031; Guangzhou, Guangdong, China).

Acknowledgments

We thank the enrolled families for their kind support and cooperation.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.914207/full#supplementary-material

SUPPLEMENT FIGURE

Representative images of FEVR (case 4, GA 38W, BW 3100g, IVD +3).

References

1. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. (2003) 112:e518–25. doi: 10.1542/peds.2004-1180
2. Azad R, Gilbert C, Gangwe AB, Zhao P, Wu WC, Sarbajna P, et al. Retinopathy of prematurity: how to prevent the third epidemics in developing countries. Asia Pac J Ophthalmol (phila). (2020) 9:440–8. doi: 10.1097/APO.0000000000000313
3. Askie LM, Darlow BA, Davis PG, Finer N, Stenson B, Vento M, et al. Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants. Cochrane Database Syst Rev. (2017) 4.CD011190. doi: 10.1002/14651858.CD011190.pub2
4. Li LH Li N, Zhao JY, Fei P, Zhang GM, Mao JB, et al. Findings of perinatal ocular examination performed on 3573, healthy full-term newborns. Br J Ophthalmol. (2013) 97:588–91. doi: 10.1136/bjophthalmol-2012-302539
5. Ratra D, Akhundova I, Das MK. Retinopathy of prematurity: like retinopathy in full-term infants. Oman J Ophthalmol. (2017) 10:167–72. doi: 10.4103/ojo.OJO_141_2016
6. Ma Y, Deng G, Ma J, Liu J, Li S, Lu H. Universal ocular screening of 481 infants using wide-field digital imaging system. BMC Ophthalmol. (2018) 18:283. doi: 10.1186/s12886-018-0943-7
7. Padhi TR, Rath S, Jalali S, Pradhani L, Kesawrani S, Nayak M, et al. Larger and near-term baby retinopathy: a rare case series. Eye. (2015) 29:286–9. doi: 10.1038/eye.2014.253
8. Chen LN HX, Huang LP, A. survey of high risk factors affecting retinopathy in full-term infants in China. Int J Ophthalmol. (2012) 5:177–80. doi: 10.3980/j.issn.2222-3959.2012.02.12
9. Savarese M, Spinelli E, Gandolfi F, Lemma V, Di Fruscio G, Padoan R, et al. Familial exudative vitreoretinopathy caused by a homonymous mutation in Tspan12 in a cystic fibrosis infant. Ophthalmic Genet. (2014) 35:184–6. doi: 10.3109/13816810.2013.811270
10. Lee J, Dammann O. Perinatal infection, inflammation, and retinopathy of prematurity. Semin Fetal Neonatal Med. (2012) 17:26–9. doi: 10.1016/j.siny.2011.08.007
11. Wang Z, Liu CH, Huang S, Chen J. Wnt signaling in vascular eye diseases. Prog Retin Eye Res. (2019) 70:110–33. doi: 10.1016/j.preteyeres.2018.11.008
12. Wang Z, Chen C, Sun L, Zhang A, Liu C, Huang L, et al. Symmetry of folds in fevr: a genotype-phenotype correlation study. Exp Eye Res. (2019) 186:107720. doi: 10.1016/j.exer.2019.107720

13. International Committee for the Classification of Retinopathy of P. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. (2005) 123:991–9. doi: 10.1001/archopht.123.7.991

14. Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. (2003) 121:1684–94. doi: 10.1001/archopht.121.12.1684

15. Emami S, Isaac M, Mireskandari K, Tehrani N. Laser treatment for retinopathy of prematurity: a decade since etop. Ophthalmology. (2019) 126:639–41. doi: 10.1016/j.ophtha.2018.12.012

16. Ling K, Liao P, Wang N, Chao A, Chen K, Chen T, et al. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina. (2020) 40:1793–803. doi: 10.1097/IAE.0000000000002663

17. Parag K, Shah VP, Smita S, Karandikar, Ratnesh Ranjan, Venkatapathy Narendran, Narendran Kalpana. Retinopathy of prematurity past, present and future. World J Clin Pediatr. (2016) 3:35–46. doi: 10.5409/wcjp.v5.i.35

18. Titawattanakul Y, Kulvichit K, Varadisai A, Marvichak A. Outcomes of pre-early treatment for retinopathy of prematurity (Pre-Etop). Clin Ophthalmol. (2020) 14:3393–7. doi: 10.2147/OPTH.S268997

19. Chen C, Sun L, Li S, Huang L, Zhang T, Wang Z, et al. The spectrum of genetic mutations in patients with asymptomatic mild familial exudative vitreoretinopathy. Exp Eye Res. (2020) 192:107941. doi: 10.1016/j.exer.2020.107941

20. Zhang T, Wang Z, Sun L, Li S, Huang L, Liu C, et al. Ultra-wide-field scanning laser ophthalmoscopy and optical coherence tomography in fevr: findings and its diagnostic ability. British J Ophthalmol. (2020) 104:1–7. doi: 10.1136/bjophthalmol-2020-316226

21. Johnson K, Mintz-Hittner H, Conley Y, Ferrell R. X-linked exudative vitreoretinopathy caused by an arginine to leucine substitution (r121l) in the norrie disease protein. Clin Genet. (1996) 50:113–5. doi: 10.1111/j.1399-0004.1996.tb02363.x

22. Tian T, Zhang X, Zhang Q, Zhao P. Fzd4 variable reduction in norrin signaling activity caused by novel mutations in Fzd4 identified in patients with familial exudative vitreoretinopathy. Mol Vis. (2019) 25:60–9.

23. Vinekar A, Govindaraj J, Jayadev C, Kumar AK, Sharma P, Mangalesh S, et al. Universal ocular screening of 1021 term infants using wide-field digital imaging in a single public hospital in India - a pilot study. Acta Ophthalmol. (2015) 93:e372–6. doi: 10.1111/aos.12685

24. Huang H, Huang C, Hung P, Chang Y. Hypoxic-ischemic retinal injury in rat pups. Pediatr Res. (2012) 72:224–31. doi: 10.1038/pr.2012.74

25. Lemma K, Misker D, Kassa M, Abdullah H, Otayo K. Determinants of birth asphyxia among newborn live births in public hospitals of gomo and goda zones, Southern Ethiopia. BMC Pediatr. (2022) 22:280. doi: 10.1186/s12887-022-03342-x

26. Dickinson JL, Sale MM, Passmore A, FitzGerald LM, Wheatley CM, Burdon KP, et al. Mutations in the Ndp gene: contribution to norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clin Exp Ophthalmol. (2006) 34:682–8. doi: 10.1111/j.1442-9003.2006.01314.x

27. Kondo H, Kusaka S, Yoshinaga A, Uchio E, Tawara A, Hayashi K, et al. Mutations in the Tipasin12 gene in japanese patients with familial exudative vitreoretinopathy. Am J Ophthalmol. (2011) 151:1095–100.e1. doi: 10.1016/j.ajo.2010.11.026

28. Paes K, Wang E, Henze K, Vogel P, Read R, Suwanichkul A, et al. Frizzled 4 Is required for retinal angiogenesis and maintenance of the blood-retina barrier. Invest Ophthalmol Vis Sci. (2011) 52:6452–61. doi: 10.1167/iovs.10-7146

29. Lai MB, Zhang C, Shi J, Johnson V, Khandan L, McVey J, et al. Tipasin12 is a norrin co-receptor that amplifies frizzled4 ligand selectivity and signaling. Cell Rep. (2017) 19:2809–22. doi: 10.1016/j.celrep.2017.06.004

30. Gunay M, Celik G, Tuten A, Karatekin G, Bardak H, Ovaili F. Characteristics of severe retinopathy of prematurity in infants with birth weight above 1500 grams at a referral center in Turkey. PLoS ONE. (2016) 11:e0161692. doi: 10.1371/journal.pone.0161692

31. John VI, McClintic JI, Hess DI, Berrocal AM. Retinopathy of prematurity versus familial exudative vitreoretinopathy: report on clinical and angiographic findings. Ophthalmic Surg Lasers Imaging Retina. (2016) 47:14–9. doi: 10.3928/23258160-20151214-02

32. Tanenbaum R, Acon D, El Hamichi S, Negron C, Berrocal AM. Unrecognized roper in a child with a novel pathogenic variant in Znf408 gene. Ophthalmic Genet. (2020) 1–4. doi: 10.1080/13816810.2020.1778735

33. Hocaoglu M, Karacorlu M, Sayman Muslubas I, Ersöz M, Arf S. Anatomical and functional outcomes following vitreoretinectomy for advanced familial exudative vitreoretinopathy: a single surgeon’s experience. Brit J Ophthalmol. (2017) 101:946–50. doi: 10.1136/bjophthalmol-2016-309526

34. Kim H, Yu Y. Retinopathy of prematurity-mimicking retinopathy in full-term babies. Korean J Ophthalmol. (2016) 29:128–32. doi: 10.3341/kjo.1998.1.2.98

35. Smith LE, Hard AL, Hellstrom A. The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment. Clin Perinatol. (2013) 40:201–14. doi: 10.1016/j.clp.2013.02.002